



**90th Annual Meeting of the American Thyroid Association
September 30 – October 3, 2021**

Name	Ineligible Company	Relationships
Guiseppe Barbesino	Horizon Pharmaceuticals	Consultant
Andrew Bauer	IBSA Pharmaceuticals	Consultant
Antonio Bianco	Synthonics, Allergan, BLA Tech	Consultant
Marcia Brose	Eisai, Bayer, Loxo, Blueprint Exelixis	Consultant, Honoraria, Grant Funding Grant Funding
Kenneth Burman	UpToDate, IBSA, Astra Zeneca, Exelixis FDA	Honoraria Advisory Committee
Maria Cabanillas	Lilly Bayer, Exelixis	Consultant Advisory Board
Francesco Celi	Acella, Amneal IBSA	Consultant Advisory Board
Christine Dierks	Eisai, Lilly, Novartis, Gilead	Advisory Board
Rossella Elisei	Eisai, Exelixis, Bayer, Loxo, Ipsen	Consultant
James Fagin	Loxo Oncology	Consultant
Suzanne Freitag	Horizon Therapeutics, WL Gore, Proiferous	Consultant
Andrew Gianoukakis	Eisai, Exelixis	Advisory Board
Thomas Giordano	Interpace Biosciences	Consultant
Whitney Goldner	Roche	Grant/Research Support
Laszlo Hegedus	ISBA	Research Support, Consultant, Honoraria
Anthony Hollenberg	Eli Lilly, GSK, Novo Nordisk, AstraZeneca	Data Safety Monitoring Committee MTC
Mimi Hu	Blueprint Medicine, Eli Lilly Eli Lilly	Speaker's Bureau, Grant/Research Support Consultant
George Kahaly	Vindico LLC	Speaker
Bhavana Konda	Bristol Myers Squibb, Merck, Eisai, Xencor, Eli Lilly	Grant/Research Support
Theodore Laetsch	Bayer, Pfizer Bayer, Loxo Oncology, Novartis, Collectars, Eli Lilly, Juno Health, Y-mAbs Therapeutics	Grant/Research Support Consultant Consultant
Sophie Leboulleux	EISAI, Lilly	Honoraria
Angela Leung	China Merck, Medical Education Resources ISBA Institute Biochemique Vertice Pharma	Speaker's Bureau Grant/Research Support Consultant
Miles Miller	Pfizer Genentech	Editorial Assistance Material Transfer Agreement
Ilaria Muller	Sanofi Genzyme	Speaker
Carmelo Nucera	Kineticos	Survey
Do-Youn Oh	Astra Zeneca, Novartis, Genetech Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS, Celgene, Bariliea, Turning Point	Advisory Board
Jonathan Russell	Baxter Scientific	Consultant
Manisha Shah	Eli-Lilly and Merck	Grant/Research Support

Padmanee Sharma	Achelois, Adaptive Biotechnologies, Affini-T, Apricity, BioAlta, BioNTech, Candel Therapeutics, Catalio, Codiak, Constellation, Dragonfly, Earli, Enable Medicine, Glympse, Hummingbird, ImaginAb, Infinity Pharma, Jounce, JSL Health, Lava Therapeutics, Lytix, Marker, Oncolytics, PBM Capital, Phenomic AI, Sporos, Time Bioventures, Trained Therapeutix, Two Bear Capital, Venn Biosciences	Consultant, Stock Ownership, or Advisory Board
Steven Sherman	Exelixis Exelixis, Eisai, Eli Lilly	Researcher Consultant
Julie Ann Sosa	Exelixis, Eli Lilly DMC of the MTC Consortium Registry supported by GSK, Novo Nordisk, Astra Zeneca, Eli Lilly	Grant/Research Support Member
Christine Spitzweg	Lilly; Bayer	Honoraria
Marius Stan	Valenza Biotech, Tolmar, Medicxi, Siemens Healthcare, Third Rock Ventures	Consultant, Research Support
Ralph Tufano	Medtronic RGS Healthcare Pulse Biosciences	Speaker, Consultant Speaker, Consultant Consultant
Steven Waguespack	Bayer	Speaker's Bureau & Consultant
Jonathan Wasserman	Ipsen Pharmaceuticals	Advisory Board
Roy Weiss	Prizm, LLC	Co-Founder
Lori Wirth	Roche, Lilly Novartis, Bayer, Blueprint, Eisai, Lilly, Merck	Grant/Research Support Consultant

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

All of the other planners, faculty, or individuals in control of content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.